Bo Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Yao has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
Wei Lu
GeneX (Zhejiang) Precision Medicine Co., Ltd, Hangzhou 311100, China
11 shared publicationsYongan Ren
9 shared publicationsKe Ge
7 shared publicationsZichen Hong
Department of Chemistry, Zhejiang University, Hangzhou 310058, China
7 shared publicationsMin Wang
6 shared publications- Guangzhong Ma
Zhejiang Key Laboratory of Excited-State Energy Conversion and Energy Storage, Department of Chemistry, Zhejiang University, Hangzhou 310058, China
5 shared publications
Latest Publications
- 2 July 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (8) , 5673-5682
Self-Assembed G-Quadruplex Nanowires for Energy Transfer over Micrometers
G-quadruplex-based nanowires (G-wires) are promising candidates for high-performance photonic and electronic nanomaterials, yet their utility is restricted by the discontinuous phosphodiester linkages inherent in the current assembly methods. These discontinuities impair structural stability, limit axial growth, and compromise the long-range energy transfer efficiency. Herein, by employing hairpin-structured splint strands to template the high-yield cyclization of poly(dC) DNA, we enable rolling circle amplification to produce ultralong poly(dG) DNA that spontaneously self-assembles into micrometer-scale G-wires with a continuous phosphate backbone. Furthermore, a nucleic acid-specific fluorescent probe, thiazole orange (TO), showed a highly efficient long-range energy transfer through G-wires, compared with double-stranded DNA (dsDNA) and G-quadruplex monomers.
- 2 July 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (8) , 5673-5682
Self-Assembed G-Quadruplex Nanowires for Energy Transfer over Micrometers
G-quadruplex-based nanowires (G-wires) are promising candidates for high-performance photonic and electronic nanomaterials, yet their utility is restricted by the discontinuous phosphodiester linkages inherent in the current assembly methods. These discontinuities impair structural stability, limit axial growth, and compromise the long-range energy transfer efficiency. Herein, by employing hairpin-structured splint strands to template the high-yield cyclization of poly(dC) DNA, we enable rolling circle amplification to produce ultralong poly(dG) DNA that spontaneously self-assembles into micrometer-scale G-wires with a continuous phosphate backbone. Furthermore, a nucleic acid-specific fluorescent probe, thiazole orange (TO), showed a highly efficient long-range energy transfer through G-wires, compared with double-stranded DNA (dsDNA) and G-quadruplex monomers.
- 20 February 2026
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (3) , 2356-2365
Membrane-Confined CRISPR-Cas12a Activation via Split Activator for Wash-Free Detection of Tumor-Specific Extracellular Vesicles
Current CRISPR-Cas12a biosensing systems for protein analysis rely on the release of a blocked activator from an aptamer through a competitive mechanism. However, the design of the complementary length between the activator and the aptamer involves a critical trade-off: excessively long sequences impede aptamer-target binding, whereas overly short sequences fail to activate Cas12a effectively. To overcome this limitation, we split the full-length Cas12a activator into two short single-stranded DNA fragments (S1 and S2; 10 nt each). S1 was specifically sequestered within the hairpin structure of an allosteric aptamer. The binding of the target protein to the aptamer triggered a conformational change, exposing S1 and thereby enabling its assembly with S2 to activate Cas12a. The strategy successfully preserved the binding affinity of the aptamer without compromising the efficiency of Cas12a activation. Furthermore, we anchored the Cas12a substrate to the membrane surface of extracellular vesicles (EVs) via hydrophobic interactions, localizing the cleavage reaction to the EVs interface and thereby significantly enhancing local catalytic efficiency. Finally, the strategy provided highly sensitive detection of tumor-specific EVs, not only accurately distinguishing cancer patients from healthy individuals (77.5% accuracy for early-stage and 100% for advanced-stage) but also holding potential for monitoring dynamic postoperative changes. Overall, our study provided a wash-free, one-pot detection platform for EVs analysis and established a new paradigm for CRISPR-based clinical diagnostics.
- 20 February 2026
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 11 (3) , 2356-2365
Membrane-Confined CRISPR-Cas12a Activation via Split Activator for Wash-Free Detection of Tumor-Specific Extracellular Vesicles
Current CRISPR-Cas12a biosensing systems for protein analysis rely on the release of a blocked activator from an aptamer through a competitive mechanism. However, the design of the complementary length between the activator and the aptamer involves a critical trade-off: excessively long sequences impede aptamer-target binding, whereas overly short sequences fail to activate Cas12a effectively. To overcome this limitation, we split the full-length Cas12a activator into two short single-stranded DNA fragments (S1 and S2; 10 nt each). S1 was specifically sequestered within the hairpin structure of an allosteric aptamer. The binding of the target protein to the aptamer triggered a conformational change, exposing S1 and thereby enabling its assembly with S2 to activate Cas12a. The strategy successfully preserved the binding affinity of the aptamer without compromising the efficiency of Cas12a activation. Furthermore, we anchored the Cas12a substrate to the membrane surface of extracellular vesicles (EVs) via hydrophobic interactions, localizing the cleavage reaction to the EVs interface and thereby significantly enhancing local catalytic efficiency. Finally, the strategy provided highly sensitive detection of tumor-specific EVs, not only accurately distinguishing cancer patients from healthy individuals (77.5% accuracy for early-stage and 100% for advanced-stage) but also holding potential for monitoring dynamic postoperative changes. Overall, our study provided a wash-free, one-pot detection platform for EVs analysis and established a new paradigm for CRISPR-based clinical diagnostics.
- 4 November 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (11) , 9086-9092
Understanding the Origin of Surface Plasmon Resonance Microscopy Signals in Cell-Based Molecular Interaction Measurements
Surface plasmon resonance microscopy (SPRM) is widely used for label-free imaging of biomolecular interactions at cell membranes. In cell-based assays, SPRM often produces distinctive patterns, such as edge-dominated signals and spatially heterogeneous binding kinetics, yet the physical origins of these features remain incompletely understood and cannot be resolved by SPRM alone. Here, we combine SPRM with depth- and time-resolved confocal fluorescence imaging to address this question. Using lectin binding on fixed cells as a model system, we show that SPRM signals primarily originate from ligand binding within the portion of the membrane exposed to the evanescent field, with additional contributions from binding-induced membrane deformation. We also find that local membrane features strongly correlate with kinetic heterogeneity. These results provide direct experimental evidence clarifying SPRM signal formation in cell-based measurements and offer practical guidance for accurate quantification and interpretation in label-free plasmonic imaging of cellular interfaces.
- 4 November 2025
- Published by American Chemical Society (ACS) in ACS Sensors
- Vol. 10 (11) , 9086-9092
Understanding the Origin of Surface Plasmon Resonance Microscopy Signals in Cell-Based Molecular Interaction Measurements
Surface plasmon resonance microscopy (SPRM) is widely used for label-free imaging of biomolecular interactions at cell membranes. In cell-based assays, SPRM often produces distinctive patterns, such as edge-dominated signals and spatially heterogeneous binding kinetics, yet the physical origins of these features remain incompletely understood and cannot be resolved by SPRM alone. Here, we combine SPRM with depth- and time-resolved confocal fluorescence imaging to address this question. Using lectin binding on fixed cells as a model system, we show that SPRM signals primarily originate from ligand binding within the portion of the membrane exposed to the evanescent field, with additional contributions from binding-induced membrane deformation. We also find that local membrane features strongly correlate with kinetic heterogeneity. These results provide direct experimental evidence clarifying SPRM signal formation in cell-based measurements and offer practical guidance for accurate quantification and interpretation in label-free plasmonic imaging of cellular interfaces.
- 12 May 2025
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 191
Advancing cancer diagnosis through surface plasmon resonance detection of extracellular vesicles
- 12 May 2025
- Published by Elsevier in TrAC Trends in Analytical Chemistry
- Vol. 191
Advancing cancer diagnosis through surface plasmon resonance detection of extracellular vesicles
- 24 December 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (1) , 1037
Correction to “Dual-Recognition-Mediated Autocatalytic Amplification Assay for the Subpopulations of PD-L1 Positive Extracellular Vesicle”
- 24 December 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 97 (1) , 1037
Correction to “Dual-Recognition-Mediated Autocatalytic Amplification Assay for the Subpopulations of PD-L1 Positive Extracellular Vesicle”
- 11 December 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (51) , 20230-20238
Label-Free Impedance Imaging of Single Extracellular Vesicles Using Interferometric Electrochemical Microscopy
Extracellular vesicles (EVs) are pivotal in various biological processes and diseases, yet their small size and heterogeneity pose challenges for single EV quantification. We introduce interferometric electrochemical microscopy (iECM), a sensitive label-free technique that combines interferometric scattering and electrochemical impedance imaging. This method enables the quantification of the impedance of single EVs, providing unique insights into their electrochemical properties, and allows for the simultaneous measurement of size and real-time monitoring of antibody binding. Notably, we discovered that the impedance spectra of EVs can serve as specific fingerprints to differentiate EVs from cancerous and healthy cells, establishing iECM as a unique platform for EV characterization and classification.
- 11 December 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (51) , 20230-20238
Label-Free Impedance Imaging of Single Extracellular Vesicles Using Interferometric Electrochemical Microscopy
Extracellular vesicles (EVs) are pivotal in various biological processes and diseases, yet their small size and heterogeneity pose challenges for single EV quantification. We introduce interferometric electrochemical microscopy (iECM), a sensitive label-free technique that combines interferometric scattering and electrochemical impedance imaging. This method enables the quantification of the impedance of single EVs, providing unique insights into their electrochemical properties, and allows for the simultaneous measurement of size and real-time monitoring of antibody binding. Notably, we discovered that the impedance spectra of EVs can serve as specific fingerprints to differentiate EVs from cancerous and healthy cells, establishing iECM as a unique platform for EV characterization and classification.
- 5 November 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (46) , 18384-18391
Patient-Derived Organoids on a Microarray for Drug Resistance Study in Breast Cancer
Drug resistance is always a challenge in cancer treatment, whether for chemotherapy, targeting, or immunotherapy. Although tumor cell lines are derived from cancer patients, they gradually lost the original characteristics, including heterogeneity and tumor microenvironment (TME), during the long period of in vitro culturing. Therefore, it is urgent to use patient-derived tumor models instead of cancer cell lines to study tumor drug resistance. Herein, we developed a microarray device that serves as a platform for high-throughput and three-dimensional culture of breast cancer patient-derived organoids (BCOs) and investigated their resistance to adriamycin (ADM). Coupled with fluorescence microscopy, this system enabled on-chip drug response monitoring and cell viability assessment without the consumption of a large number of tumor cells. The organoids were divided into a resistant BCO group (RBCO) and a sensitive BCO group (SBCO) according to their half-inhibitory concentration (IC50). Different from cancer cell lines, BCOs demonstrated obvious heterogeneity in drug treatment. Ivermectin (IVM), a broad-spectrum antiparasitic agent approved by the Food and Drug Administration (FDA), was observed to synergistically augment ADM-induced cytotoxicity in organoids. The BCO chip provides a promising platform for investigation of drug resistance and preclinical drug screening based on clinical samples.
- 5 November 2024
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 96 (46) , 18384-18391
Patient-Derived Organoids on a Microarray for Drug Resistance Study in Breast Cancer
Drug resistance is always a challenge in cancer treatment, whether for chemotherapy, targeting, or immunotherapy. Although tumor cell lines are derived from cancer patients, they gradually lost the original characteristics, including heterogeneity and tumor microenvironment (TME), during the long period of in vitro culturing. Therefore, it is urgent to use patient-derived tumor models instead of cancer cell lines to study tumor drug resistance. Herein, we developed a microarray device that serves as a platform for high-throughput and three-dimensional culture of breast cancer patient-derived organoids (BCOs) and investigated their resistance to adriamycin (ADM). Coupled with fluorescence microscopy, this system enabled on-chip drug response monitoring and cell viability assessment without the consumption of a large number of tumor cells. The organoids were divided into a resistant BCO group (RBCO) and a sensitive BCO group (SBCO) according to their half-inhibitory concentration (IC50). Different from cancer cell lines, BCOs demonstrated obvious heterogeneity in drug treatment. Ivermectin (IVM), a broad-spectrum antiparasitic agent approved by the Food and Drug Administration (FDA), was observed to synergistically augment ADM-induced cytotoxicity in organoids. The BCO chip provides a promising platform for investigation of drug resistance and preclinical drug screening based on clinical samples.
- 2 September 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (30) , e2401990
Microchip Based Isolation and Drug Delivery of Patient‐Derived Extracellular Vesicles Against Their Homologous Tumor
Extracellular vesicles (EVs) have demonstrated significant potential in drug delivery and anti‐tumor therapy. Despite this promising strategy, challenges such as specific targeting, EVs purification persist. In this study, a personalized nanodrug delivery platform using patient‐derived tumor EVs (PT‐EVs) based on a microchip is presented. The microchip integrates multiple functions, including capture, enrichment, drug loading, and elution of PT‐EVs. The isolation and drug‐carrying procedures are completed within a 12 h timeframe, achieving a recovery rate of 65%, significantly surpassing the conventional ultracentrifuge (UC) method. Furthermore, PT‐EVs derived from patient tumor models are first utilized as natural drug carriers, capitalizing on their inherent homing ability to precisely target homologous tumors. Lenvatinib and doxorubicin (DOX), two commonly utilized drugs in the clinical treatment of hepatocellular carcinoma (HCC), are loaded into PT‐EVs and delivered to a matched in vitro tumor model that recapitulates original tumors for drug susceptibility testing. As is proven, PT‐EVs exhibit robust tumor cell targeting and efficient receptor‐mediated cellular uptake, and the efficacy of chemotherapeutic drugs is improved significantly. These results suggest that this platform could be a valuable tool for efficient isolation of PT‐EVs and personalized drug customization, particularly when working with limited clinical samples, thus supporting personalized and precision medicine.
- 2 September 2024
- Published by Wiley in Advanced Healthcare Materials
- Vol. 13 (30) , e2401990
Microchip Based Isolation and Drug Delivery of Patient‐Derived Extracellular Vesicles Against Their Homologous Tumor
Extracellular vesicles (EVs) have demonstrated significant potential in drug delivery and anti‐tumor therapy. Despite this promising strategy, challenges such as specific targeting, EVs purification persist. In this study, a personalized nanodrug delivery platform using patient‐derived tumor EVs (PT‐EVs) based on a microchip is presented. The microchip integrates multiple functions, including capture, enrichment, drug loading, and elution of PT‐EVs. The isolation and drug‐carrying procedures are completed within a 12 h timeframe, achieving a recovery rate of 65%, significantly surpassing the conventional ultracentrifuge (UC) method. Furthermore, PT‐EVs derived from patient tumor models are first utilized as natural drug carriers, capitalizing on their inherent homing ability to precisely target homologous tumors. Lenvatinib and doxorubicin (DOX), two commonly utilized drugs in the clinical treatment of hepatocellular carcinoma (HCC), are loaded into PT‐EVs and delivered to a matched in vitro tumor model that recapitulates original tumors for drug susceptibility testing. As is proven, PT‐EVs exhibit robust tumor cell targeting and efficient receptor‐mediated cellular uptake, and the efficacy of chemotherapeutic drugs is improved significantly. These results suggest that this platform could be a valuable tool for efficient isolation of PT‐EVs and personalized drug customization, particularly when working with limited clinical samples, thus supporting personalized and precision medicine.